Loading...

Newron Pharmaceuticals S.p.A.

NP5.DEXETRA
Healthcare
Medical - Pharmaceuticals
7.37
0.00(0.00%)

Newron Pharmaceuticals S.p.A. (NP5.DE) Stock Competitors & Peer Comparison

See (NP5.DE) competitors and their performances in Stock Market.

Peer Comparison Table: Medical - Pharmaceuticals Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
NP5.DE€7.37+0.00%151.5M8.83€0.86N/A
NOVC.DE€91.40-2.42%406.7B22.91€3.99N/A
4AB.DU€167.40+0.00%301BN/AN/A+3.45%
W8A.DE€10.07+0.04%8.8B-1.62-€6.30+4.90%
RDC.DE€101.60+0.00%2.1B-58.85-€1.74N/A
SAE.DE€88.30+0.00%1.6B-26.60-€3.32N/A
2LYA.F€1.88-0.74%152.2M-23.47-€0.08N/A
5EA.DE€19.20+0.00%0N/AN/AN/A

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

NP5.DE vs NOVC.DE Comparison August 2025

NP5.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NP5.DE stands at 151.5M. In comparison, NOVC.DE has a market cap of 406.7B. Regarding current trading prices, NP5.DE is priced at €7.37, while NOVC.DE trades at €91.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NP5.DE currently has a P/E ratio of 8.83, whereas NOVC.DE's P/E ratio is 22.91. In terms of profitability, NP5.DE's ROE is -1.09%, compared to NOVC.DE's ROE of +0.86%. Regarding short-term risk, NP5.DE is more volatile compared to NOVC.DE. This indicates potentially higher risk in terms of short-term price fluctuations for NP5.DE.Check NOVC.DE's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions

;